Soleno Therapeutics ( (SLNO) ) has released its Q2 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases, with its first commercial product being VYKAT XR, a treatment for hyperphagia in Prader-Willi syndrome patients.
In its latest earnings report, Soleno Therapeutics highlighted the successful U.S. launch of VYKAT XR, following its FDA approval in March 2025, and reported financial results for the second quarter of 2025. The company also announced the submission of a Marketing Authorization Application to the European Medicines Agency for VYKAT XR, known as DCCR in the EU.
Key financial metrics for the second quarter of 2025 included a net product revenue of $32.7 million, primarily driven by VYKAT XR sales, and a net loss of $4.7 million, which marked a significant improvement from the $21.9 million loss in the same period of 2024. Soleno also raised $230 million in gross proceeds through a stock offering, bolstering its cash reserves to support ongoing operations and future growth.
The company reported a decrease in research and development expenses compared to the previous year, while selling, general, and administrative expenses increased due to the commercial launch of VYKAT XR. Soleno’s management expressed optimism about the product’s market reception and its potential to address unmet needs in the Prader-Willi syndrome community.
Looking ahead, Soleno Therapeutics is focused on expanding the reach of VYKAT XR and continuing to build value for its shareholders, while maintaining its commitment to addressing the needs of the Prader-Willi syndrome community through innovative therapeutic solutions.